... the ECDP writing committee down-graded recommendations regarding bile acid sequestrant use, recommending bile acid sequestrants only as optional secondary agents for consideration in patients intolerant to ezetimibe. For clarification, the writing committee has also included new information on diagnostic categories of heterozygous and homozygous familial hypercholesterolemia, based on clinical criteria with and without genetic testing... Keyword: dyslipidemia. Keyword: ezetimibe.
Cardiovascular Diseases (8), Endocrine Disorders (1), Blood Disorders and Hematology (1) Cardiovascular Diseases (2), Hyperlipoproteinemia Type II (1), Dyslipidemias (1), more mentions
Based on dyslipidemia ( < 40mg/dL), low level of HDL-C was associated with the risk of mood disorder in both male and female, however, only females showed statistically significant (HR: 1.097, 95% CI: 1.012-1.189. Based on quartile-based approach, females with low levels of HDL-C ( < 47mg/dL) and males with high levels of HDL-C (≥ 59mg/dL) were ...
Neuroscience (12), Blood Disorders and Hematology (1) Mood Disorders (12), Dyslipidemias (1), more mentions
Multivariate analysis revealed that hyperlipidemia was significantly associated with idiopathic SEL (odds ratio = 3.74, 95% confidence interval = 1.31-10.64) AbstractText: Our data suggest that aberrant lipid metabolism is related to the pathogenesis of idiopathic SEL and that LSS patients with idiopathic SEL have more severe pain than do those without ...
Anti-Obesity and Weight Loss (2), Muscular and Skeletal Diseases (1) Hyperlipidemias (2), Radiculopathy (1), Back Pain (1), more mentions
The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia..
... had more medical care, including outpatient care and hospitalizations, and took more hypertension and dyslipidemia medications, whereas hospitalizations for more than 60 days were significantly more frequent in the ... events for NHCS participants was significantly greater in patients without a previous history of dyslipidemia or who did not have outpatient care.
Cardiovascular Diseases (3), Blood Disorders and Hematology (2) Dyslipidemias (2), Cardiovascular Diseases (2), Myocardial Infarction (1), more mentions
... patients with overt cardiovascular disease, elevated baseline C-reactive protein, or high level of cholesterol AbstractText: The findings from this systematic review suggest a role for statins in COPD patients with coexisting cardiovascular disease, evidence of increased systemic inflammation, or hyperlipidemia, in terms of improving exercise tolerance and pulmonary function.
Thyroid hormones have important effects on cellular development, growth, and metabolism and are necessary for the healthy function of almost all tissues. Hyperthyroid patients with excess thyroid hormone levels experience tachycardia, fatigue, muscle wasting, and osteoporosis. However, although high thyroid hormone levels have adverse effects, efforts have been made to harness the beneficial effects, such as reduced serum low-density lipoprotein (LDL) cholesterol levels, elevated basal metabolic rate, and weight loss. Thyroid hormones interact with nuclear thyroid hormone receptors (TRs), and cholesterol levels are reduced through TRβ, whereas extrahepatic adverse actions are primarily connected to TRα. Thus, to develop a useful compound for clinical use, efforts have been focusing on developing compounds with isomer-specific functions based on the structure of thyroid hormones, i.e., thyromimetics that are liver and/or TRβ specific. In this short review, we discuss the development of the early thyromimetics that enabled, through modern molecular techniques, the progress towards improved design of TRβ-selective thyromimetics. We also address the early promise shown in human clinical trials and the current status of these drugs and other emerging compounds.
Anti-Obesity and Weight Loss (1), Muscular and Skeletal Diseases (1) Osteoporosis (1), Tachycardia (1), Hyperlipidemias (1), more mentions
OBJECTIVE: In real life, in a substantial proportion of gouty patients receiving urate-lowering therapy (ULT), urate levels are not maintained below the target of 6 mg/dL. We aimed to search for factors associated with poor control of serum urate levels (sUA) in a large population of gouty patients receiving ULT.
METHODS: This cross-sectional study involved adults with gout in primary care who were receiving ULT. Demographics, gout history, comorbidities, lifestyle, clinical factors, concomitant treatments and laboratory data were compared in well-controlled gout (sUA ≤ 6 mg/dL) versus poorly-controlled gout (sUA > 6 mg/dL) on univariate and multivariate analyses.
RESULTS: Among the 1995 patients receiving ULT, only 445 (22.3%) had reached the target of 6 mg/dL sUA. Such patients had a lower rate of gout flares within the previous year than patients without the target (1.7±1.4 vs. 2.1±1.4, p < 0.0001). The main factors associated with poor sUA level control in multivariate analysis were low high-density lipoprotein-cholesterol level (adjusted odds ratio 0.5, 95% confidence interval 0.26 to 0.96; p=0.04), high total cholesterol level (1.83, 1.29 to 2.60; p=0.0007), increased waist circumference (1.55, 1.11 to 2.13; p=0.008) and alcohol consumption (1.52, 1.15 to 2.00; p=0.003).
CONCLUSION: Dyslipidaemia, abdominal obesity and alcohol consumption are the main factors associated with a poor response to ULT. Knowledge of these factors might help physicians identify cases of gout that may be less likely to achieve target urate level. This article is protected by copyright. All rights reserved.
Men's Health (6), Anti-Obesity and Weight Loss (2), Blood Disorders and Hematology (1) Gout (6), Dyslipidemias (1), Abdominal Obesity (1), more mentions
They were more frequently female (p <0.001) and with a higher rate of obesity-related co-morbidity conditions such as diabetes mellitus (p = 0.005), arterial hypertension (p <0.001), and hyperlipidemia (p = 0.001) compared with the other groups. At the 5-year follow-up, all-cause and cardiac deaths were less frequent in obese patients than in the other groups (p ...
Anti-Obesity and Weight Loss (11), Cardiovascular Diseases (1), Endocrine Disorders (1) Myocardial Infarction (3), Obesity (3), Hypertension (1), more mentions
We created body size phenotypes defined by body mass index categories (underweight, normal weight, overweight, and obesity) and 3 metabolic abnormalities (diabetes, hypertension, and hyperlipidemia. The primary endpoints were the first record of 1 of 4 cardiovascular presentations (coronary heart disease [CHD], cerebrovascular disease, heart failure, and peripheral vascular disease).During a mean follow-up of 5.4 years, obese individuals ...
Anti-Obesity and Weight Loss (10), Cardiovascular Diseases (7), Endocrine Disorders (1) Cardiovascular Diseases (4), Heart Failure (4), Coronary Disease (2), more mentions
BACKGROUND: Affecting a substantial proportion of adults, chronic kidney disease (CKD) is considered a major risk factor for cardiovascular (CV) events. It has been reported that patients with CKD are underserved when it comes to CV risk reduction efforts.
STUDY DESIGN: Prespecified subgroup analysis of a randomized controlled trial.
SETTING & PARTICIPANTS: Adults with CKD and at least 1 uncontrolled CV risk factor were enrolled from 56 pharmacies across Alberta, Canada.
INTERVENTION: Patient, laboratory, and individualized CV risk assessments; treatment recommendations; prescription adaptation(s) and/or initiation as necessary; and regular monthly follow-up for 3 months.
OUTCOMES: The primary outcome was change in estimated CV risk from baseline to 3 months after randomization. Secondary outcomes were change between baseline and 3 months after randomization in individual CV risk factors (ie, low-density lipoprotein cholesterol, blood pressure, and hemoglobin A1c), risk for developing end-stage renal disease, and medication use and dosage; tobacco cessation 3 months after randomization for those who used tobacco at baseline; and the impact of rural versus urban residence on the difference in change in estimated CV risk.
MEASUREMENTS: CV risk was estimated using the Framingham, UK Prospective Diabetes Study, and international risk assessment equations depending on the patients' comorbid conditions.
RESULTS: 290 of the 723 participants enrolled in RxEACH had CKD. After adjusting for baseline values, the difference in change in CV risk was 20% (P<0.001). Changes of 0.2mmol/L in low-density lipoprotein cholesterol concentration (P=0.004), 10.5mmHg in systolic blood pressure (P<0.001), 0.7% in hemoglobin A1c concentration (P<0.001), and 19.6% in smoking cessation (P=0.04) were observed when comparing the intervention and control groups. There was a larger reduction in CV risk in patients living in rural locations versus those living in urban areas.
LIMITATIONS: The 3-month follow-up period can be considered relatively short. It is possible that larger reduction in CV risk could have been observed with a longer follow up period.
CONCLUSIONS: This subgroup analysis demonstrated that a community pharmacy-based intervention program reduced CV risk and improved control of individual CV risk factors. This represents a promising approach to identifying and managing patients with CKD that could have important public health implications.
... years to ascertain the presence of type 2 diabetes, hypertension, and dyslipidemia... had higher remission rates and lower incidence rates of hypertension and dyslipidemia than did nonsurgery group 1 (P<0.05 for all comparisons... and effective remission and prevention of type 2 diabetes, hypertension, and dyslipidemia after Roux-en-Y gastric bypass.
Endocrine Disorders (6), Cardiovascular Diseases (3), Blood Disorders and Hematology (3) Diabetes Mellitus, Type 2 (5), Dyslipidemias (3), Hypertension (3), more mentions
... and distant metastases were analyzed AbstractText: Autologous fat grafting patients and control patients were of similar body mass index, smoking status, and BRCA status. Patients who underwent fat grafting were significantly younger than control patients and were less likely to have diabetes, hypertension, or hyperlipidemia. The two groups represented similar distributions of BRCA status, Oncotype scores, and hormone receptor status.
Oncology (3), Cardiovascular Diseases (1), Endocrine Disorders (1) Neoplasms (2), Breast Neoplasms (2), Hypertension (1), more mentions
Stepwise regression was used to identify factors predicting the ISWT distance. Age, gender, body mass index, height, weight; presence of hypertension, dyslipidemia or diabetes; smoking and physical activity were independent variables. ISWT distance was the dependent variable. The 25th, 50th and 75th percentiles of the ISWT distance were used as reference values AbstractText: Age and gender explained 27% of the ...
Cardiovascular Diseases (1), Endocrine Disorders (1), Anti-Obesity and Weight Loss (1) Dyslipidemias (1), Hypertension (1), Diabetes Mellitus (1), more mentions
... MetS on 30-day morbidity and mortality following elective lumbar spinal fusion SUMMARY OF BACKGROUND DATA.: Metabolic syndrome (MetS) is a variable combination of hypertension, obesity, elevated fasting plasma glucose, and dyslipidemia.MetS has been associated with an increased risk of post-operative morbidity and mortality in multiple surgical settings.
Cardiovascular Diseases (2), Endocrine Disorders (1), Blood Disorders and Hematology (1) Kidney Failure (2), Hypertension (2), Sepsis (2), more mentions
... age (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.01-1.14; P = .026), congestive heart failure (HR, 4.7; 95% CI, 1.29-16.9; P = .019), and dyslipidemia (HR, 0.34; 95% CI, 0.12-0.99; P = .049) as independent predictors of AFS loss, whereas PLVI was not (HR, 2.6; 95% CI, 0.83-8.39; P ...
Blood Disorders and Hematology (1) Congestive Heart Failure (2), Dyslipidemias (1), Arterial Occlusive Diseases (1), more mentions
Patients with both hypertension and dyslipidemia have 4× higher annual progression rate compared with subjects without these risk factors (0.398 m/s/y versus 0.102 m/s/y. When only subjects 55 years old and under were considered, the progression rate of augmentation index was higher in subjects with more risk factors (1.15%/y versus 1.50%/y versus 2.99%/y ...
Cardiovascular Diseases (2), Blood Disorders and Hematology (1) Dyslipidemias (1), Hypertension (1), Cardiovascular Diseases (1), more mentions